IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Domvanalimab (Primary) ; Fluorouracil (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Zimberelimab (Primary)
- Indications Carcinoid tumour; Carcinoma; Gastrointestinal cancer; Gestational trophoblastic disease; Lung cancer; Malignant thymoma; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Peritoneal cancer; Thoracic neoplasms; Thymoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms IMMUNORARE5
- 31 Jan 2025 New trial record